论文信息 - Alterations in mGluR5 Expression and Signaling in Lewy Body Disease and in Transgenic Models of Alpha-Synucleinopathy

Alterations in mGluR5 Expression and Signaling in Lewy Body Disease and in Transgenic Models of Alpha-Synucleinopathy – Implications for Excitotoxicity

Dementia with Lewy bodies (DLB) and Parkinson's Disease (PD) are neurodegenerative disorders of the aging population characterized by the abnormal accumulation of alpha-synuclein (alpha-syn). Previous studies have suggested that excitotoxicity may contribute to neurodegeneration in these disorders, however the underlying mechanisms and their relationship to alpha-syn remain unclear. For this study we proposed that accumulation of alpha-syn might result in alterations in metabotropic glutamate receptors (mGluR), particularly mGluR5 which has been linked to deficits in murine models of PD. In this context, levels of mGluR5 were analyzed in the brains of PD and DLB human cases and alpha-syn transgenic (tg) mice and compared to age-matched, unimpaired controls, we report a 40% increase in the levels of mGluR5 and beta-arrestin immunoreactivity in the frontal cortex, hippocampus and putamen in DLB cases and in the putamen in PD cases. In the hippocampus, mGluR5 was more abundant in the CA3 region and co-localized with alpha-syn aggregates. Similarly, in the hippocampus and basal ganglia of alpha-syn tg mice, levels of mGluR5 were increased and mGluR5 and alpha-syn were co-localized and co-immunoprecipated, suggesting that alpha-syn interferes with mGluR5 trafficking. The increased levels of mGluR5 were accompanied by a concomitant increase in the activation of downstream signaling components including ERK, Elk-1 and CREB. Consistent with the increased accumulation of alpha-syn and alterations in mGluR5 in cognitive- and motor-associated brain regions, these mice displayed impaired performance in the water maze and pole test, these behavioral alterations were reversed with the mGluR5 antagonist, MPEP. Taken together the results from study suggest that mGluR5 may directly interact with alpha-syn resulting in its over activation and that this over activation may contribute to excitotoxic cell death in select neuronal regions. These results highlight the therapeutic importance of mGluR5 antagonists in alpha-synucleinopathies.

[1] Qin Li,et al. A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys , 2010, Neurobiology of Disease.

[2] L. Grégoire,et al. Effect of l‐Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys , 2010, Journal of neurochemistry.

[3] Yasuhiko Izumi,et al. Dopamine facilitates alpha-synuclein oligomerization in human neuroblastoma SH-SY5Y cells. , 2010, Biochemical and biophysical research communications.

[4] B. Hyman,et al. Dopamine-Induced Conformational Changes in Alpha-Synuclein , 2009, PloS one.

[5] L. Grégoire,et al. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys. , 2009, Parkinsonism & related disorders.

[6] R. Rosenfeld. Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[7] M. Amalric,et al. Metabotropic Glutamate Receptors 5 Blockade Reverses Spatial Memory Deficits in a Mouse Model of Parkinson's Disease , 2009, Neuropsychopharmacology.

[8] E. Masliah,et al. Mechanism of alpha-synuclein oligomerization and membrane interaction: theoretical approach to unstructured proteins studies. , 2008, Nanomedicine : nanotechnology, biology, and medicine.

[9] E. Masliah,et al. Mechanisms of Hybrid Oligomer Formation in the Pathogenesis of Combined Alzheimer's and Parkinson's Diseases , 2008, PloS one.

[10] R. Sanchez-Pernaute,et al. Enhanced binding of metabotropic glutamate receptor type 5 (mGluR5) PET tracers in the brain of parkinsonian primates , 2008, NeuroImage.

[11] A. Nieoullon,et al. Preferential vulnerability of mesencephalic dopamine neurons to glutamate transporter dysfunction , 2008, Journal of neurochemistry.

[12] M. Mattson,et al. Calcium and neurodegeneration , 2007, Aging cell.

[13] Mark H. Ellisman,et al. High-resolution large-scale mosaic imaging using multiphoton microscopy to characterize transgenic mouse models of human neurological disorders , 2007, Neuroinformatics.

[14] S. Thompson,et al. Glutamate‐mediated excitotoxicity in neonatal hippocampal neurons is mediated by mGluR‐induced release of Ca++ from intracellular stores and is prevented by estradiol , 2006, The European journal of neuroscience.

[15] M. Onofrj,et al. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium , 2006, Neurology.

[16] M E Martone,et al. Automated microscopy system for mosaic acquisition and processing , 2006, Journal of microscopy.

[17] J. M. Phillips,et al. Blockade of mGluR5 glutamate receptors in the subthalamic nucleus ameliorates motor asymmetry in an animal model of Parkinson's disease , 2006 .

[18] J. M. Phillips,et al. Blockade of mGluR glutamate receptors in the subthalamic nucleus ameliorates motor asymmetry in an animal model of Parkinson's disease. , 2006, The European journal of neuroscience.

[19] D. Grandy,et al. Interactions between Metabotropic Glutamate 5 and Adenosine A2A Receptors in Normal and Parkinsonian Mice , 2005, The Journal of Neuroscience.

[20] G. Halliday,et al. A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease. , 2005, Brain : a journal of neurology.

[21] T. Schachtman,et al. The role of metabotropic glutamate receptor 5 in learning and memory processes. , 2005, Drug news & perspectives.

[22] M. Amalric,et al. Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson’s disease , 2005, Psychopharmacology.

[23] K. Fuxe,et al. Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP , 2005, Brain Research.

[24] M. Jahanshahi,et al. The basal ganglia: anatomy, physiology, and pharmacology. , 2004, The Psychiatric clinics of North America.

[25] A. Sidhu,et al. Does α‐synuclein modulate dopaminergic synaptic content and tone at the synapse? , 2004 .

[26] M. Amalric,et al. Simultaneous Blockade of Adenosine A2A and Metabotropic Glutamate mGlu5 Receptors Increase their Efficacy in Reversing Parkinsonian Deficits in Rats , 2004, Neuropsychopharmacology.

[27] J. Trojanowski,et al. More than just two peas in a pod: common amyloidogenic properties of tau and α-synuclein in neurodegenerative diseases , 2004, Trends in Neurosciences.

[28] Hyoung-Gon Lee,et al. Aberrant expression of metabotropic glutamate receptor 2 in the vulnerable neurons of Alzheimer’s disease , 2004, Acta Neuropathologica.

[29] D. Manahan‐Vaughan,et al. Regulation by metabotropic glutamate receptor 5 of LTP in the dentate gyrus of freely moving rats: relevance for learning and memory formation. , 2004, Cerebral cortex.

[30] Giuseppe Battaglia,et al. Endogenous Activation of mGlu5 Metabotropic Glutamate Receptors Contributes to the Development of Nigro-Striatal Damage Induced by 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine in Mice , 2004, The Journal of Neuroscience.

[31] Jean-Christophe Rochet,et al. Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. , 2004, Journal of molecular neuroscience : MN.

[32] Philippe Vernier,et al. Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse? , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33] D. Dickson,et al. Diffuse Lewy body disease: light and electron microscopic immunocytochemistry of senile plaques , 2004, Acta Neuropathologica.

[34] Hyoung-Gon Lee,et al. The role of metabotropic glutamate receptors in Alzheimer's disease. , 2004, Acta neurobiologiae experimentalis.

[35] P. Janak,et al. Effect of the mGluR5 antagonist 6-methyl-2-(phenylethynyl)pyridine (MPEP) on the acute locomotor stimulant properties of cocaine, d-amphetamine, and the dopamine reuptake inhibitor GBR12909 in mice , 2004, Psychopharmacology.

[36] R. Albin,et al. mGluRs: a target for pharmacotherapy in Parkinson disease , 2003, Experimental Neurology.

[37] E. Masliah,et al. The neuroprotective effects of Cerebrolysin™ in a transgenic model of Alzheimer’s disease are associated with improved behavioral performance , 2003, Journal of Neural Transmission.

[38] M. Amalric,et al. Metabotropic Glutamate 5 Receptor Blockade Alleviates Akinesia by Normalizing Activity of Selective Basal-Ganglia Structures in Parkinsonian Rats , 2003, The Journal of Neuroscience.

[39] M. Jaber,et al. Motor behaviour deficits and their histopathological and functional correlates in the nigrostriatal system of dopamine transporter knockout mice , 2003, Neuroscience.

[40] P Jeffrey Conn,et al. Glutamate Receptors and Parkinson’s Disease , 2003, Drugs & aging.

[41] T. Oury,et al. Cytoplasmic aggregates of phosphorylated extracellular signal-regulated protein kinases in Lewy body diseases. , 2002, The American journal of pathology.

[42] S. Ferguson,et al. Mechanisms of metabotropic glutamate receptor desensitization: role in the patterning of effector enzyme activation , 2002, Neurochemistry International.

[43] P. Lansbury,et al. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. , 2002, Journal of molecular biology.

[44] George Perry,et al. Differential Regulation of Glutamate Receptors in Alzheimer’s Disease , 2002, Neurosignals.

[45] M. Amalric,et al. Chronic But Not Acute Treatment with a Metabotropic Glutamate 5 Receptor Antagonist Reverses the Akinetic Deficits in a Rat Model of Parkinsonism , 2002, The Journal of Neuroscience.

[46] L A Hansen,et al. Cognitive profiles differ in autopsy-confirmed frontotemporal dementia and AD , 2002, Neurology.

[47] Nancy A. Jenkins,et al. Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[48] Makoto Hashimoto,et al. Differential neuropathological alterations in transgenic mice expressing α‐synuclein from the platelet‐derived growth factor and Thy‐1 promoters , 2002, Journal of neuroscience research.

[49] M. Zigmond,et al. A Role for α-Synuclein in the Regulation of Dopamine Biosynthesis , 2002, The Journal of Neuroscience.

[50] G. Halliday,et al. Selective hippocampal neuron loss in dementia with Lewy bodies , 2002, Annals of neurology.

[51] D. Price,et al. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[52] M. Zigmond,et al. A role for alpha-synuclein in the regulation of dopamine biosynthesis. , 2002, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[53] P. H. Anborgh,et al. Agonist-stimulated and tonic internalization of metabotropic glutamate receptor 1a in human embryonic kidney 293 cells: agonist-stimulated endocytosis is beta-arrestin1 isoform-specific. , 2001, Molecular pharmacology.

[54] I. Kanazawa,et al. α-Synuclein Affects the MAPK Pathway and Accelerates Cell Death* , 2001, The Journal of Biological Chemistry.

[55] K. Fuxe,et al. The Selective mGlu5 Receptor Agonist CHPG Inhibits Quinpirole-Induced Turning in 6-Hydroxydopamine-Lesioned Rats and Modulates the Binding Characteristics of Dopamine D2 Receptors in the Rat Striatum Interactions with Adenosine A2a Receptors , 2001, Neuropsychopharmacology.

[56] Glenda M. Halliday,et al. Cortical Lewy body pathology in the diagnosis of dementia , 2001, Acta Neuropathologica.

[57] J. Wierońska,et al. Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats , 2001, Neuropharmacology.

[58] F. Nicoletti,et al. Metabotropic Glutamate Receptor Subtypes as Targets for Neuroprotective Drugs , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[59] B. Shastry,et al. Parkinson disease: etiology, pathogenesis and future of gene therapy , 2001, Neuroscience Research.

[60] S. Mundell,et al. Agonist‐induced internalization of the metabotropic glutamate receptor 1a is arrestin‐ and dynamin‐dependent , 2001, Journal of neurochemistry.

[61] E. Aronica,et al. Immunohistochemical localization of group I and II metabotropic glutamate receptors in control and amyotrophic lateral sclerosis human spinal cord: upregulation in reactive astrocytes , 2001, Neuroscience.

[62] Ichiro Kanazawa,et al. alpha-Synuclein forms a complex with transcription factor Elk-1. , 2001 .

[63] I. Kanazawa,et al. α‐Synuclein forms a complex with transcription factor Elk‐1 , 2001, Journal of neurochemistry.

[64] J. Greenamyre. Glutamatergic influences on the basal ganglia. , 2001, Clinical neuropharmacology.

[65] S. Ferré,et al. The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors. , 2001, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[66] A. Faden,et al. Selective mGluR5 antagonists MPEP and SIB‐1893 decrease NMDA or glutamate‐mediated neuronal toxicity through actions that reflect NMDA receptor antagonism , 2000, British journal of pharmacology.

[67] P. Conn,et al. Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders. , 2000, Pharmacology & therapeutics.

[68] T. Chase,et al. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism , 2000, Trends in Neurosciences.

[69] D. Dickson,et al. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson’s disease , 2000, Acta Neuropathologica.

[70] J. Trojanowski,et al. Synucleins Are Developmentally Expressed, and α-Synuclein Regulates the Size of the Presynaptic Vesicular Pool in Primary Hippocampal Neurons , 2000, The Journal of Neuroscience.